Intramural Research Program (IRP) scientists are encouraged to produce innovative basic, translational and clinical research—a research paradigm often termed “bench-to-bedside.” Basic science aims to understand the genetic and cellular basis of a disease or diseases. Clinical science aims to apply therapies to those diseases. Translational science, perhaps the most complex in many ways, aims to discover, develop, and validate therapies—and molecular pharmacology is central to that challenge. At its most basic, molecular pharmacology is the study of molecular actions and interactions of a drug or therapy, but the science behind this discipline is enormously diverse, involving molecular biologists, biochemists, chemists, pharmacologists, toxicologists, statisticians, and experts in bioinformatics.
Many Institutes and Centers in the IRP support research programs that discover, design, develop, and test novel compounds for use as candidate therapeutics, including:
IRP researchers have access to world-class tools to support this science, such as:
Taken together, our scientists have the molecular pharmacological tools, infrastructure, and determination to help bridge the ever-widening gap between the bench and the bedside.